Alvotech (ALVO)
5.48
-0.30
(-5.19%)
USD |
NASDAQ |
Oct 12, 14:12
Alvotech Enterprise Value : 3.371B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 3.371B |
| October 08, 2026 | 3.332B |
| October 07, 2026 | 3.396B |
| October 06, 2026 | 3.500B |
| October 05, 2026 | 3.489B |
| October 02, 2026 | 3.254B |
| October 01, 2026 | 3.314B |
| September 30, 2026 | 3.379B |
| September 29, 2026 | 3.421B |
| September 28, 2026 | 3.503B |
| September 25, 2026 | 3.361B |
| September 24, 2026 | 3.407B |
| September 23, 2026 | 3.382B |
| September 22, 2026 | 3.393B |
| September 21, 2026 | 3.407B |
| September 18, 2026 | 3.404B |
| September 17, 2026 | 3.214B |
| September 16, 2026 | 3.129B |
| September 15, 2026 | 3.100B |
| September 14, 2026 | 3.111B |
| September 11, 2026 | 3.197B |
| September 10, 2026 | 3.179B |
| September 09, 2026 | 3.168B |
| September 08, 2026 | 3.161B |
| September 04, 2026 | 3.207B |
| Date | Value |
|---|---|
| September 03, 2026 | 3.229B |
| September 02, 2026 | 3.214B |
| September 01, 2026 | 3.179B |
| August 31, 2026 | 3.161B |
| August 28, 2026 | 3.075B |
| August 27, 2026 | 3.050B |
| August 26, 2026 | 3.061B |
| August 25, 2026 | 3.111B |
| August 24, 2026 | 3.182B |
| August 21, 2026 | 2.890B |
| August 20, 2026 | 2.833B |
| August 19, 2026 | 2.733B |
| August 18, 2026 | 2.718B |
| August 17, 2026 | 2.693B |
| August 14, 2026 | 2.756B |
| August 13, 2026 | 2.768B |
| August 12, 2026 | 2.740B |
| August 11, 2026 | 2.665B |
| August 10, 2026 | 2.654B |
| August 07, 2026 | 2.669B |
| August 06, 2026 | 2.665B |
| August 05, 2026 | 2.651B |
| August 04, 2026 | 2.679B |
| August 03, 2026 | 2.661B |
| July 31, 2026 | 2.779B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 591.52M |
| Amgen, Inc. | 267.59B |
| Regeneron Pharmaceuticals, Inc. | 71.89B |
| Anika Therapeutics, Inc. | 248.88M |
| BioCryst Pharmaceuticals, Inc. | 2.666B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.82M |
| Revenue (Quarterly) | 105.77M |
| Total Expenses (Quarterly) | 172.59M |
| EPS Diluted (Quarterly) | -0.1873 |
| Gross Profit Margin (Quarterly) | 50.65% |
| Profit Margin (Quarterly) | -63.17% |
| Earnings Yield | -10.17% |
| Operating Earnings Yield | 2.53% |
| Normalized Earnings Yield | -10.17 |